









Markets
/
Stocks
/
nasdaq-amgn
/

Amgen Inc

AMGN



View Detailed Chart

317.740USD

+0.360+0.11%

Close 12/12, 16:00（ET）Quotes delayed by 15 min

171.10BMarket Cap

24.40P/E TTM



Amgen Inc

317.740

+0.360+0.11%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.11%

5 Days

-3.68%

1 Month

-5.43%

6 Months

+7.63%

Year to Date

+21.91%

1 Year

+17.41%

View Detailed Chart

TradingKey Stock Score of Amgen Inc

Currency: USD Updated: 2025-12-12

Key Insights

Amgen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 45/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 326.54.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amgen Inc's Score

Industry at a Glance

Industry Ranking

45 / 159

Overall Ranking

124 / 4592

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 35 analysts

Buy

Current Rating

326.535

Target Price

+1.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amgen Inc Highlights

StrengthsRisks

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.98% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.

Fairly Valued

The company’s latest PE is 24.40, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 451.47M shares, increasing 0.01% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 11.29K shares of this stock.

Amgen Inc News

Bernstein cuts Amgen PT on uncertainty over obesity drug candidate MariTide

** Bernstein cuts PT on drugmaker Amgen AMGN.O to $350 from $380, citing uncertainty over co's key obesity drug candidate MariTide** New PT is nearly a 19% upside to stock's last close** Brokerage says MariTide is a higher-risk-and-high-reward opportunity** Adds obesity pipeline is advancing...

ReutersThu, Feb 20

Amgen profits rise, next MariTide studies start by mid-year

Feb 4 (Reuters) - Amgen AMGN.O posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

ReutersTue, Feb 4